NervGen Pharma appoints Keith Vendola as new chief financial officer
Updated
Updated · MarketWatch · Apr 27
NervGen Pharma appoints Keith Vendola as new chief financial officer
6 articles · Updated · MarketWatch · Apr 27
Vendola, previously CFO at clinical-stage cell-therapy company Wugen, succeeds William Adams, who retired in March.
NervGen’s CEO Adam Rogers had served as interim finance chief during the search for Adams’s replacement.
The Vancouver-based biopharmaceutical company is in the clinical stage, and the leadership transition aims to support its ongoing development and financial strategy.
Why did NervGen ditch the Canadian stock exchange ahead of its most critical drug trial?
Is the hype for NervGen's new drug premature given the high failure rate of Phase 3 trials?
How can spinal cord injury patients join the pivotal RESTORE trial for NervGen's promising drug?
Is hiring an experienced CFO enough to navigate the biotech sector's brutal funding environment?
What do new gait analyses reveal about NVG-291's potential to reverse spinal cord injury?
Will a simple injection outperform brain-computer implants in the race to cure paralysis?